NewAmsterdam Pharma Company NAMS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $457.61M-38.9% | $490M-36.5% | $538.41M+27.4% | $563.86M— | $748.42M— | ||
| $178.5M— | $146.24M— | $164.54M— | —— | —— | ||
| $658.04M-19.5% | $675.7M-21.7% | $732.33M+67.2% | $769.85M— | $817.3M— | ||
| $379K+59.2% | $383K+58.3% | $323K+39.8% | $312K— | $238K— | ||
| $375K-25.3% | $407K-23.8% | $439K-26.0% | $470K— | $502K— | ||
| $732.64M-10.5% | $769.28M-11.0% | $786.43M+79.1% | $815.11M— | $818.41M— | ||
| $26.59M+14.9% | $24.58M-3.9% | $20.36M-46.1% | $23.77M+10.5% | $23.15M+12.6% | ||
| —— | —— | —— | —— | —— | ||
| $67.42M+64.8% | $85.79M-19.8% | $58.27M+41.2% | $36.51M— | $40.91M— | ||
| $67.42M+64.2% | $85.85M-19.9% | $58.36M-3.3% | $36.62M— | $41.05M— | ||
| $14.59M+4.5% | $14.28M+6.2% | $14.11M+23.4% | $14.01M— | $13.97M— | ||
| -$810.83M-35.6% | -$762.39M-36.5% | -$687.47M-47.4% | -$615.46M— | -$598.1M— | ||
| $665.22M-14.4% | $683.43M-9.8% | $728.07M+92.2% | $778.5M+101% | $777.36M+88.8% | ||
| $732.64M-10.5% | $769.28M-11.0% | $786.43M+79.1% | $815.11M— | $818.41M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NewAmsterdam Pharma Company cover its short-term obligations?
- Its current ratio is 9.76 — current assets exceed current liabilities.
- Where does NewAmsterdam Pharma Company's balance sheet data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.